Resumo

MUNOZ ANGULO, Natalia; ARSANIOS MARTIN, Daniel  e  CUBIDES DIAZ, Diego Alejandro. Therapeutic niche of ceftazidime-avibactam against gram-negative bacteria resistant to carbapenemics in Colombia. Univ. Med. [online]. 2021, vol.62, n.2, e31930.  Epub 15-Maio-2021. ISSN 0041-9095.  https://doi.org/10.11144/javeriana.umed62-2.nich.

Antibiotic resistance is a major public health problem worldwide, because it increases morbidity and mortality to a large number of pathologies, being responsible for 700,000 deaths per year. It is estimated that by 2050 it will account for up to 10 million deaths per year, becoming the leading cause of mortality over cardiovascular disease and cancer. This discouraging panorama has prompted the research on new antimicrobials, some of which, such as ceftazidime-avibactam (CAZ-AVI), have already been introduced into clínical practice. CAZ-AVI is a combination of a third generation cephalosporin and a new non-β-lactam β-lactamase inhibitor active against multidrug-resistant gram-negative bacteria (MDR), which, due to its high efficacy and low incidence of adverse effects, has been approved for the treatment of complicated urinary tract infections, complicated intra-abdominal infections and ventilator-associated pneumonia. A narrative review of the literature was carried out covering the main topics related to this antimicrobial, as well as what has been reported so far in our country.

Palavras-chave : ceftazidime-avibactam; Enterobacteriaceae; carbapenemases; antibiotic resistence.

        · resumo em Espanhol     · texto em Espanhol     · Espanhol ( pdf )